0001127602-18-007774.txt : 20180222
0001127602-18-007774.hdr.sgml : 20180222
20180222170056
ACCESSION NUMBER: 0001127602-18-007774
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180220
FILED AS OF DATE: 20180222
DATE AS OF CHANGE: 20180222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Macdonald R. Loch
CENTRAL INDEX KEY: 0001653008
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37568
FILM NUMBER: 18633351
MAIL ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1600
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edge Therapeutics, Inc.
CENTRAL INDEX KEY: 0001472091
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264231384
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 CONNELL DRIVE
STREET 2: SUITE 4000
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
BUSINESS PHONE: 800-208-3343
MAIL ADDRESS:
STREET 1: 300 CONNELL DRIVE
STREET 2: SUITE 4000
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2018-02-20
0001472091
Edge Therapeutics, Inc.
EDGE
0001653008
Macdonald R. Loch
300 CONNELL DRIVE,
SUITE 4000
BERKELEY HEIGHTS
NJ
07922
1
1
Chief Scientific Officer
Common Stock
2018-02-20
4
S
0
5000
13.75
D
590602
D
Common Stock
2018-02-21
4
S
0
5000
13.82
D
585602
D
Common Stock
2018-02-22
4
S
0
2500
14.49
D
583102
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.66 to $13.86 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.68 to $14.05 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.23 to $14.76 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Albert N. Marchio II, attorney-in-fact
2018-02-22